Capstone Holding Corp. Stock Price, News & Analysis

Capstone Holding Corp. reinstated a Tax Benefit Plan, declaring a dividend distribution of one Right for each outstanding share of common stock to shareholders of record as of May 1, 2024. Each Right entitles the holder to purchase Series A Preferred Stock at an exercise price of $5. The Board aims to protect the Company's Tax Benefits through the Benefit Plan until April 1, 2027.

Capstone Therapeutics Corp. held its Annual Meeting on March 2, 2023, primarily to elect three Class III Directors and ratify the appointment of GBQ Partners, LLC as its independent accounting firm. BP Peptides, LLC, a majority shareholder, holds 77.26% of outstanding shares and facilitated the meeting through written consent, allowing the election of John M. Holliman, III, Matthew E. Lipman, and Frederic J. Feldman until 2026. GBQ Partners was ratified for the fiscal years ending December 31, 2022, and 2023. Capstone has shifted its focus from biotechnology to managing TotalStone, LLC, a construction materials company, following the discontinuation of its drug development business.

Capstone Holding Corp. (OTCQB: CAPS) announced that BP Peptides, LLC converted $1,938,746 of accrued interest and debt into 78,333 shares of its common stock at an exercise price of $24.75 per share. This conversion increases Brookstone's total shares to 121,774, representing 77.26% of the company’s total stock. Capstone's operations shifted from biotechnology to managing interests in construction materials and equity interests in Diamond Products. For more details, refer to the 2021 Annual Report.

Capstone Therapeutics Corp. (OTCQB:CAPS) has officially changed its name to Capstone Holding Corp. as of February 25, 2022. This name change reflects the Company's strategic shift away from pharmaceutical development, following the licensing of its LipimetiX Development assets in December 2021. Capstone has since acquired a majority stake in a profitable building materials company, TotalStone, LLC, and a minority stake in Diamond Products, LLC, a consumer wellness firm. The new name aligns with its current focus on these operating businesses.

Capstone Therapeutics Corp. held its Annual Meeting of Stockholders on December 1, 2021, where two directors were elected and the appointment of GBQ Partners, LLC as independent accountants was ratified for the fiscal year ending December 31, 2021. The majority shareholder, BP Peptides, LLC, controlling 54.8% of shares, requested a consent voting format for the meeting. Capstone has transitioned from a biotechnology focus to managing construction materials through its subsidiary, TotalStone, LLC.

Capstone Therapeutics has acquired a minority interest in Diamond Products, LLC, a sexual wellness holding company, through its subsidiary Capstone Beta LLC. The acquisition, valued at around $8 million, involves a promissory note issued to Brookstone Partners, which holds a significant equity interest in Diamond. The transaction was overseen by a special committee of independent directors to ensure transparency and due diligence. This move marks a strategic shift as Capstone moves away from biotechnology into consumer products, specifically in the adult wellness sector.